

# Contents

Preface	xi
<b>1 Concepts</b>	<b>1</b>
1.1 Introduction	1
1.2 Cost-effectiveness data and the parameters of interest	2
1.3 The cost-effectiveness plane, the ICER and INB	5
1.4 Outline	8
<b>2 Parameter Estimation for Non-censored Data</b>	<b>11</b>
2.1 Introduction	11
2.2 Cost	12
2.2.1 Sample means for estimating incremental cost	12
2.2.2 Using multiple regression models	14
2.2.3 Transformation (and the retransformation problem)	15
2.2.4 Generalized linear models	17
2.2.5 Two-part models for excess zeros	18
2.2.6 Cost prediction models	19
2.3 Effectiveness	20
2.3.1 Probability of surviving	21
2.3.2 Mean survival time	21
2.3.3 Mean quality-adjusted survival time	22
2.3.4 Mean quality-adjusted survival: controlling for baseline utility	24
2.4 Summary	25
<b>3 Parameter Estimation for Censored Data</b>	<b>27</b>
3.1 Introduction	27
3.2 Mean Cost	28
3.2.1 Direct (Lin) method	29
3.2.2 Inverse-probability weighting	31
3.3 Effectiveness	34
3.3.1 Probability of surviving	34

**viii Contents**

3.3.2	Mean survival time	36
3.3.3	Mean quality-adjusted survival time	39
3.4	Summary	42
<b>4</b>	<b>Cost-effectiveness Analysis</b>	<b>43</b>
4.1	Introduction	43
4.2	Incremental cost-effectiveness ratio	44
4.3	Incremental net benefit	49
4.4	The cost-effectiveness acceptability curve	51
4.5	Using bootstrap methods	54
4.6	A Bayesian incremental net benefit approach	57
4.7	Kinked thresholds	60
4.8	Summary	64
<b>5</b>	<b>Cost-effectiveness Analysis: Examples</b>	<b>67</b>
5.1	Introduction	67
5.2	The CADET-Hp trial	67
5.3	Symptomatic hormone-resistant prostate cancer	72
5.4	The Canadian implantable defibrillator study (CIDS)	77
5.5	The EVALUATE trial	82
5.6	Bayesian approach applied to the UK PDS study	86
5.7	Summary	90
<b>6</b>	<b>Power and Sample Size Determination</b>	<b>93</b>
6.1	Introduction	93
6.2	Approaches based on the cost-effectiveness plane	94
6.2.1	Briggs and Gray	95
6.2.2	Willan and O'Brien	98
6.2.3	Gardiner <i>et al.</i>	101
6.3	The classical approach based on net benefit	103
6.3.1	The method	103
6.3.2	Example	105
6.4	Bayesian take on the classical approach	106
6.4.1	The Method	106
6.4.2	Example	107
6.5	The value of information approach	108
6.5.1	The method	108
6.5.2	Example	114
6.6	Summary	116
<b>7</b>	<b>Covariate Adjustment and Sub-group Analysis</b>	<b>117</b>
7.1	Introduction	117
7.2	Non-censored data	118
7.2.1	Example, non-censored data	121

**Contents ix**

7.3	Censored data	129
7.3.1	Cost	131
7.3.2	Quality-adjusted survival time	132
7.3.3	Survival time	134
7.3.4	The Canadian implantable defibrillator study (CIDS)	135
7.3.5	The evaluate trial	138
7.4	Summary	142
<b>8</b>	<b>Multicenter and Multinational Trials</b>	<b>145</b>
8.1	Introduction	145
8.2	Background to multinational cost-effectiveness	147
8.3	Fixed effect approaches	151
8.3.1	Willke <i>et al.</i>	151
8.3.2	Cook <i>et al.</i>	152
8.4	Random effects approaches	154
8.4.1	Aggregate level analysis: multicenter trials	154
8.4.2	Aggregate level analysis: multinational trials	156
8.4.3	Hierarchical modeling	162
8.5	Summary	164
<b>9</b>	<b>Modeling Cost-effectiveness</b>	<b>165</b>
9.1	Introduction	165
9.2	A general framework for modeling cost-effectiveness results	166
9.3	Case study: an economic appraisal of the goal study	167
9.3.1	The GOAL study	168
9.3.2	Standard approach to estimating cost-effectiveness	170
9.3.3	An alternative approach to estimating cost-effectiveness	171
9.3.4	Comparing the two analyses of GOAL	179
9.4	Summary	180
	References	183
	Author Index	193
	Subject Index	195
	Series List	197

